Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.49 USD
+0.26 (4.97%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.49 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
FHTX 5.49 +0.26(4.97%)
Will FHTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FHTX
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Other News for FHTX
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics appoints Kristian Humer as chief financial officer
Foghorn Therapeutics Appoints Kristian Humer as New CFO
Foghorn Therapeutics appoints Humer as Chief Financial Officer
FHTX Makes Notable Cross Below Critical Moving Average